Development of new radioembolization using radioisotope labeled lipiodol for hepatocellular carcinoma

2015 Fiscal Year Final Research Report

• Project/Area Number: 25461894
• Research Category: Grant-in-Aid for Scientific Research (C)
• Allocation Type: Multi-year Fund
• Section: 一般
• Research Field: Radiation science
• Research Institution: Kansai Medical University
• Principal Investigator: TANIGAWA Noboru 関西医科大学, 医学部, 教授 (90227215)
• Co-Investigator(Kenkyū-buntansha): UTSUNOMIYA KEITA 関西医科大学, 医学部, 講師 (20193914) ; KARIYA SHUJI 関西医科大学, 医学部, 准教授 (40368220) ; KOHNO YUMIKO 関西医科大学, 医学部, 助教 (10598957)
• Project Period (FY): 2013-04-01 – 2016-03-31
• Keywords: 放射性同位元素 / 肝細胞癌 / 肝動脈塞栓術

Outline of Final Research Achievements

Transarterial chemoembolization is essential for unresectable hepatocellular carcinoma. We developed new radioembolization using Y-90 labeled lipiodol. Treatment model was divided into three groups according to the embolic materials, that is, lipiodol group, Y-90 labeled lipiodol group, and no treatment group, and treatment effects were compared among the three groups. The rabbits treated with Y-90 labeled lipiodol got the longest term survival among the three groups. New radioembolization using Y-90 labeled lipiodol is thought to be effective and shown the result of which the additional effect is expected compared with the conventional embolization.

Free Research Field

IVR